HYPOCAAVI: Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy

Sponsor
University Hospital, Brest (Other)
Overall Status
Recruiting
CT.gov ID
NCT04785443
Collaborator
(none)
242
1
2
44.3
5.5

Study Details

Study Description

Brief Summary

  • Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It becomes permanent after 6 months.

  • Untreated permanent hypoparathyroidism is a source of numerous complications in general and therefore requires lifelong replacement therapy resulting in a significant deterioration in quality of life.

  • The intraoperative use of indocyanine green (ICG) angiography has recently been described as a reliable means of detecting parathyroidism and predicting the risk of postoperative hypoparathyroidism.

  • This use could prove to be a way to preserve parathyroid in vivo and thus reduce post-operative hypoparathyroidism rates.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It is most often transient but can sometimes be permanent when it persists for more than 6 months after surgery. The rates are variable, of the order of 32% for transient hypoparathyroidism and 1% for definitive hypoparathyroidism. Untreated permanent hypoparathyroidism is the source of many complications in general and therefore requires lifelong replacement therapy. The result is a significant deterioration in quality of life.

The mechanisms responsible for hypoparathyroidism during thyroidectomy are direct damage to the parathyroid glands, involuntary excision of these glands, and devascularization of these glands.

The detection of parathyroid glands and the prevention of hypoparathyroidism after thyroidectomy therefore represents a major challenge.

The intraoperative use of indocyanine green angiography has recently been described as a reliable means of detecting parathyroid and predicting the risk of postoperative hypoparathyroidism.

In addition, prior studies and intraoperative observations suggest that indocyanine green angiography during thyroid surgery may be a means of preserving parathyroid in vivo and thus reducing post-operative hypoparathyroidism rates.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
242 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Monocentric, comparative, randomized, single-blind, controlled trial against the reference methodMonocentric, comparative, randomized, single-blind, controlled trial against the reference method
Masking:
Single (Participant)
Masking Description:
Simple blind (only participant)
Primary Purpose:
Prevention
Official Title:
Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy
Actual Study Start Date :
Jun 22, 2021
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: ICG group

Patient receiving 2 or 3 intraoperative injections of indocyanine green.

Drug: ICG
During thyroidectomy surgery, the patient will received 2 or 3 injections of 5 mg as a bolus. The first one during the dissection of the first lobe, then during the dissection of the second lobe and finally if needed, a 3rd injection will be done at the end of the dissection. Patients will then be followed during 6 months.

Other: Control group

Patient benefiting from the traditional surgical act

Procedure: Control group
During thyroidectomy surgery, patients are treated according to traditional surgery with detection of parathyroids with the naked eyes. Patients will then be followed during 6 months.

Outcome Measures

Primary Outcome Measures

  1. Compare the frequency of albumin-corrected hypocalcemia (blood sugar below 2 mmol/L, a sign associated with hypoparathyroidism) postoperatively between the ICG group and the control group. [Day 2]

    Frequency of albumin-corrected hypocalcemia (≤2 mmol/L) within 48 hours postoperatively.

Secondary Outcome Measures

  1. Evaluate the contribution of ICG angiography in the modification of the rate of definitive hypoparathyroidism after total thyroidectomy. [Day 8, Month 1 and Month 6]

    Occurrence (yes/no) of albumin-corrected (<2mmol/L) postoperative hypocalcemia at D8, M1 and M6

  2. Determine the contribution of indocyanine green angiography (ICG) during the total thyroidectomy procedure for in vivo detection and preservation of parathyroid glands. [Day 0]

    Modification (yes/no) of the surgical procedure by improving the detection of parathyroids or their vascularization during thyroidectomy with the use of indocyanine green angiography.

  3. To evaluate the contribution of indocyanine green angiography in the prediction of postoperative hypocalcemia. [Day 0]

    Intraoperative parathyroid vitality score (0=devascularized parathyroid gland to 2 = vascularized thyroid gland) when using indocyanine green angiography.

  4. To determine the interest of indocyanine green angiography (ICG) in the prediction of hypoparathyroidism after total thyroidectomy. [Day 1 and Day 2]

    Occurrence (yes/no) of hypo parathormone at D1 and D2 postoperatively (<10ng/L).

  5. Compare the frequency of postoperative hypocalcemia, according to its grade (mild, moderate and deep), between the ICG group and the control group. [D1 and D2]

    Frequency of mild (asymptomatic and >1.7mmol/l), moderate (symptomatic and >1.7mmol/l) and profound (<1.7mmol/l) hypocalcemia within 48 hours postoperatively.

  6. Evaluate the tolerance of indocyanine green. [Day 1, Day 2, Day 10]

    Occurrence of an adverse event related to the injection of indocyanine green.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient having to undergo a total thyroidectomy

  • Signed consent

  • Patient beneficiary of a social security regimen

Exclusion Criteria:
  • Minor patient under 18 years old

  • Major patient protected by law or unable to give informed consent

  • Pregnant or breastfeeding woman

  • Thyroidectomy totalization

  • History of thyroid or parathyroid surgery

  • Participation refusal

  • Known allergy to ICG

  • Woman of child-bearing age not using adequate method of contraception

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHRU de Brest Brest France 29609

Sponsors and Collaborators

  • University Hospital, Brest

Investigators

  • Principal Investigator: Jean-Christophe LECLERE, PhD, CHRU de Brest

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT04785443
Other Study ID Numbers:
  • 29BRC20.0208
First Posted:
Mar 5, 2021
Last Update Posted:
Jul 8, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Brest
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 8, 2022